

Comorbidity of Fibromyalgia in Primary Knee Osteoarthritis: Potential Impact on Functional Status and Quality of Life [Corrigendum]

Mahgoub MY, Elnady BM, Abdelkader HS, Abdelhalem RA, Hassan WA. *Open Access Rheumatol.* 2020;12: 55–63. The authors apologize for this error.

The authors have advised that Table 1 on pages 58 and 59 is incorrect. The correct table is shown below.

Table 1 Baseline Characteristics of Different Groups

	Variable	KOA (n=59) Group I	KOA Patients with FM (n=32) Group II	FM (n=30) Group III	P value
Demographic	Age (years), mean \pm SD	53.4 \pm 7.2	47.3 \pm 4.6	37.5 \pm 6.9	<0.001* P1<0.001*, p2<0.001*, p3<0.001*
	BMI, mean \pm SD	33.4 \pm 3.1	33.3 \pm 3.4	29.5 \pm 3.9	<0.001* p1<0.001*, p2<0.001*, p3=0.8
	Residence (rural: urban)	34:25	22:10	18:12	0.58
	Marital status (married: not married)	49:10	23:9	19:11	0.11
	Educational level (literate: illiterate)	39:20	26:6	26:4	0.07
Clinical	Disease duration (years), median (IQR)	3 (2-5)	2 (1-3.5)	2 (2-3)	0.07
	KL grades, n (%)				
	I	16 (27.1)	18 (56.3)	----	0.02*
	II	17 (28.8)	7 (21.9)	----	
	III	26 (44.1)	7 (21.9)	----	
	VAS, median (IQR)	3 (2.0-4.75)	6 (5-8)	5 (3-7)	<0.001* p1=0.002*, p2=0.04*, p3<0.001*
	PSQI, mean \pm SD	7.5 \pm 1.7	12.5 \pm 2.5	9.1 \pm 2.7	<0.001* P1<0.001*, p2<0.001*, P3<0.001*
	PASS20, mean \pm SD	35.9 \pm 8.4	47.8 \pm 10.9	40.5 \pm 8.6	<0.001* p1=0.02*, p2=0.005*, p3<0.001*
	BDI-II, median (IQR)	5 (2-7)	14 (9-17.5)	22.5 (18-27)	<0.001* p1<0.001*, p2<0.001*, p3<0.001*
Lequesene score, median (IQR)	5 (4-7)	7 (5.5-12)	----	<0.001*	
FIQ, mean \pm SD	----	49.5 \pm 20.7	42.8 \pm 13.2	0.14	

(Continued)

Table I (Continued).

	Variable	KOA (n=59) Group I	KOA Patients with FM (n=32) Group II	FM (n=30) Group III	P value
Quality of life	Physical, mean ± SD	49.8 ± 14.7	47.6 ± 14.1	62.1 ± 14.4	<0.001* p1=<0.001*, p2=<0.001*, p3=0.5
	Cognitive, mean ± SD	55.6 ± 15	49.9 ± 16.6	51.3 ± 14.8	0.2
	Affective, mean ± SD	53.5 ± 14.3	34.4 ± 17.3	47.6 ± 15.1	<0.001* p1=0.07, p2=0.002*, p3<0.001*
	Social, mean ± SD	50.5 ± 15.2	45.8 ± 13.8	55.2 ± 12.4	0.04* P1=15, p2=0.006*, p3=0.14
	Economic, mean ± SD	55.2 ± 19.1	54.8 ± 22.5	60.9 ± 16.5	0.36
	Ego, mean ± SD	47.8 ± 16	34.9 ± 15.9	35.9 ± 14.9	<0.001* p1=0.001*, p2=0.8, p3<0.001*
Medications	Acetaminophen, n (%)	49 (83)	20 (62.5)	15 (50)	0.004*
	NSAIDs, n (%)	46 (78)	27 (84.4)	22 (73.3)	0.6
	Antidepressant, n (%)	4 (6.8)	12 (37.5)	27 (90)	<0.001*
	Gabapentinoids, n (%)	9 (15.3)	16 (50)	24 (80)	<0.001*
	Chondroprotctives, n (%)	46 (78)	21 (65.6)	0 (0)	0.3

Notes: P1: between KOA group and FM group; p2: between FM group and KOA patients with FM co-morbidity group; p3: between KOA group and KOA patients with FM co-morbidity group. *p<0.05.

Abbreviations: KOA, knee osteoarthritis; FM, fibromyalgia; BMI, body mass index; KL, Kellgren and Lawrence; VAS, visual analog scale; PSQI, Pittsburgh Sleep Quality Index; PASS20, Pain Anxiety Symptom Scale Short Form 20; BDI-II, Beck Depression Inventory; FIQ, Fibromyalgia Impact Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs.

Open Access Rheumatology: Research and Reviews

Dovepress

Publish your work in this journal

Open Access Rheumatology Research and Reviews is an international, peer-reviewed, open access journal publishing original research, reports, editorials, reviews and commentaries on all aspects of clinical and experimental rheumatology in the clinic and laboratory including the following topics: Pathology, pathophysiology of rheumatological diseases; Investigation, treatment and management

of rheumatological diseases; Clinical trials and novel pharmacological approaches for the treatment of rheumatological disorders. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/open-access-rheumatology-research-and-reviews-journal>